AFFiRiS to commence Phase II trial of its Alzheimer's vaccine candidate

Links shared publicly online about this topic.

1,587
total visits

AFFiRiS to commence Phase II trial of its Alzheimer's vaccine candidate

AFFiRiS AG will focus its Alzheimer's vaccine program on one product candidate at an unexpectedly early stage of development: the vaccine candidate AD02 is planned to enter into Phase II clinical trial early in 2010. This decision by the company immediately follows the completion of two Phase I trials with the candidates AD01 and AD02. The company based its fast decision on the first interim analysis of the secondary endpoints at the six month time point.

View full resource at news-medical.net

Tags: Vaccination, Alzheimer's Disease, Parkinson's Disease, Disease and Condition, Clinical Trial, Vaccine